A review charts the rapid growth of AAV-mediated OTOF gene replacement therapy for congenital deafness, spanning early human trials through the first FDA approval in the indication. The synthesis emphasizes how hearing recovery evidence has accumulated and how the field’s regulatory path is now providing a roadmap for other AAV inner-ear programs.